Edge Therapeutics Reports First Quarter 2018 Financial Results
01 mai 2018 06h30 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended March 31, 2018. First Quarter Financial...
Edge Therapeutics Announces Review of Strategic Alternatives
30 avr. 2018 07h00 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., April 30, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced that its Board of Directors is conducting a comprehensive review of strategic...
Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
28 mars 2018 07h00 HE
|
Edge Therapeutics, Inc.
Study Unlikely To Achieve Primary Efficacy Endpoint; DMC Recommends Discontinuation of Study No Unexpected Safety Findings Edge To Reduce Costs and Evaluate Next Steps Edge To Host Conference...
Edge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
01 mars 2018 06h30 HE
|
Edge Therapeutics, Inc.
Interim Analysis from EG-1962 Phase 3 NEWTON 2 Study in Aneurysmal Subarachnoid Hemorrhage Expected by the End of April 2018 Full Top-Line Data from NEWTON 2 Study Expected in Late 2018 BERKELEY...
Edge Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 1, 2018
26 févr. 2018 07h00 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of...
Edge Therapeutics to Present at Upcoming Investor Conferences in February
08 févr. 2018 07h00 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management...
Edge's EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis
29 déc. 2017 16h05 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management...
Edge Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference
06 nov. 2017 07h00 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management...
Edge Therapeutics Reports Third Quarter 2017 Financial Results
01 nov. 2017 07h00 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics®, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management...
Edge Therapeutics Announces Third Quarter Financial Results Conference Call on November 1, 2017
18 oct. 2017 07h00 HE
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of...